Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 37, 2013, Pages 14924-14929

  Sha, Fern ^a   Gencer, Emel Basak ^b   Georgeon, Sandrine ^b   Koide, Akiko ^a   Yasui, Norihisa ^a   Koide, Shohei ^a   Hantschel, Oliver ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b EPFL   (Switzerland)

Author keywords

Engineered proteins; Interaction proteomics; Protein interaction inhibitor; Tyrosine phosphatase

Indexed keywords

ADAPTOR PROTEIN; BCR ABL PROTEIN; BINDING PROTEIN; ENZYME ACTIVATOR; MULTIPROTEIN COMPLEX; PAXILLIN; PHOSPHOTYROSINE; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT5 PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL INTERACTION; CELL STRAIN HEK293; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SRC HOMOLOGY DOMAIN; TARGET CELL;

ENGINEERED PROTEINS; INTERACTION PROTEOMICS; PROTEIN INTERACTION INHIBITOR; TYROSINE PHOSPHATASE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HEK293 CELLS; HUMANS; K562 CELLS; MODELS, MOLECULAR; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS;

EID: 84883770456     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303640110     Document Type: Article

References (31)

1. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343-3356.
2. Hantschel O (2012) Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer 3(5-6):436-446.
3. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5(3):172-183.
4. Brehme M, et al. (2009) Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci USA 106(18):7414-7419.
5. Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112(13):4808-4817.
6. Hamilton A, et al. (2012) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119(6):1501-1510.
7. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12(8):513-526.
8. Scherr M, et al. (2006) Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107(8):3279-3287.
9. SattlerM, et al. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1(5):479-492. (Pubitemid 41039128)
10. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92(4):441-450. (Pubitemid 28101108)
11. Vogel W, Lammers R, Huang J, Ullrich A (1993) Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science 259(5101):1611-1614. (Pubitemid 23114640)
12. Mohi MG, Neel BG (2007) The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17(1):23-30. (Pubitemid 46131442)
13. Gu H, Pratt JC, Burakoff SJ, Neel BG (1998) Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol Cell 2(6):729-740. (Pubitemid 128378981)
14. Wöhrle FU, Daly RJ, Brummer T (2009) Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal 7:22.
15. Bentires-Alj M, et al. (2004) Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64(24):8816-8820. (Pubitemid 39665483)
16. Imhof D, et al. (2006) Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains: Critical roles of residues beyond the pY+3 position. J Biol Chem 281(29):20271-20282. (Pubitemid 44065802)
17. Machida K, et al. (2007) High-throughput phosphotyrosine pro filing using SH2 domains. Mol Cell 26(6):899-915. (Pubitemid 46929095)
18. Koide A, Bailey CW, Huang X, Koide S (1998) The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 284(4):1141-1151. (Pubitemid 28558562)
19. Wojcik J, et al. (2010) A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol 17(4):519-527.
20. Grebien F, et al. (2011) Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 147(2):306-319.
21. Koide A, Wojcik J, Gilbreth RN, Hoey RJ, Koide S (2012) Teaching an old scaffold new tricks: Monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol 415(2):393-405.
22. Ladbury JE, et al. (1995) Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: A reappraisal. Proc Natl Acad Sci USA 92(8):3199-3203.
23. Lechleider RJ, et al. (1993) Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor. J Biol Chem 268(29):21478-21481. (Pubitemid 23320630)
24. Waksman G, Shoelson SE, Pant N, Cowburn D, Kuriyan J (1993) Binding of a high-affinity phosphotyrosyl peptide to the Src SH2 domain: Crystal structures of the complexed and peptide-free forms. Cell 72(5):779-790. (Pubitemid 23093885)
25. Bennett AM, Tang TL, Sugimoto S, Walsh CT, Neel BG (1994) Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci USA 91(15):7335-7339.
26. Keegan K, Cooper JA (1996) Use of the two-hybrid system to detect the association of the protein-tyrosine-phosphatase, SHPTP2, with another SH2-containing protein, Grb7. Oncogene 12(7):1537-1544.
27. Li L, et al. (2011) A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells. Blood 118(6):1504 - 1515.
28. Ren Y, et al. (2004) Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem 279(9):8497-8505. (Pubitemid 38294743)
29. Araki T, Nawa H, Neel BG (2003) Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem 278(43):41677-41684. (Pubitemid 37310425)
30. Gilbreth RN, Koide S (2012) Structural insights for engineering binding proteins based on non-antibody scaffolds. Curr Opin Struct Biol 22(4):413-420.
31. Zhang Y, et al. (2011) Simultaneous binding of two peptidyl ligands by a SRC homology 2 domain. Biochemistry 50(35):7637-7646.